Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Gadopiclenol for MRI in Japanese Adults and Children
NCT06010173Phase 3Completed
- Sponsor
- Guerbet
- Start
- Jul 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gadopiclenol in Central nervous system lesion (3 cohorts), sponsored by Guerbet. Primary endpoints: Lesion Visualization on Paired Images: Border Delineation, Lesion Visualization on Paired Images: Internal Morphology and 1 more. Started Jul 2023; status: completed.
02
Drugs
gadopiclenol
03
Conditions
Central nervous system lesion
Beyond the preview
Go deeper on NCT06010173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010173.